Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 20 min 34 sec ago

Syros Pharmaceuticals Closes $53 Million Series B Financing

Mon, 10/27/2014 - 16:00
Includes Leading Public and Healthcare-Focused Funds Proceeds Will Accelerate Gene Control Programs and Platform WATERTOWN, Mass.--(Healthcare Sales & Marketing Network)--Syros Pharmaceuticals, a therapeutics company focused on discovering and develo...
Biopharmaceuticals, Venture Capital
Syros Pharmaceuticals

St. Jude Medical Receives FDA Approval of TactiCath Quartz Contact Force Ablation Catheter for Treatment of Atrial Fibrillation

Mon, 10/27/2014 - 15:52
TactiCath ablation catheter with contact-force measurement provides physicians with a new option for treating patients with atrial fibrillation ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)--St. Jude Medical, Inc. (STJ), a global medical devi...
Devices, Cardiology, FDA
St. Jude Medical, TactiCath, ablation catheter, atrial fibrillation

Zogenix Acquires U.K.-Based Brabant Pharma

Mon, 10/27/2014 - 15:47
Obtains global rights for treatment option in development for Dravet syndrome, a rare and catastrophic form of epilepsy that begins in infancy Plans to initiate Phase 3 clinical studies of Brabafen(TM) in second quarter of 2015 Conference call and we...
Biopharmaceuticals, Neurology, Mergers & Acquisitions
Zogenix, Brabant Pharma, Brabafen, fenfluramine, Dravet syndrome

Aeterna Zentaris Announces Formal Implementation of its Sales Force In Support of Selling ASCEND's EstroGel(R)

Mon, 10/27/2014 - 15:43
QUÉBEC CITY, Oct. 27, 2014 -- (Healthcare Sales & Marketing Network) - Aeterna Zentaris Inc. (AEZS) (TSX: AEZ) (the "Company") today announced the formal implementation of its own full-time U.S. sales force with field selling of ASCEND Th...
Biopharmaceuticals, Distribution
Aeterna Zentaris, ASCEND Therapeutics, EstroGel

Myriad Establishes Tumor BRACAnalysis CDx(TM) Laboratory in Europe

Fri, 10/24/2014 - 13:15
Tumor BRACAnalysis CDx Will Identify More Patients for Treatment With PARP Inhibitors SALT LAKE CITY and ZURICH, Oct. 24, 2014 -- (Healthcare Sales & Marketing Network) -- Myriad Genetics, Inc. (MYGN) today announced it has established a Tumor BRACAnaly...
Diagnostics, Oncology
Myriad Genetics, BRACAnalysis CDx, PARP inhibitors

Elite Pharmaceuticals Announces New Management Appointments

Fri, 10/24/2014 - 13:07
NORTHVALE, N.J., Oct. 24, 2014 -- (Healthcare Sales & Marketing Network) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (ELTP),a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche gene...
Biopharmaceuticals, Personnel
Elite Pharmaceuticals

Zyno Medical, LLC Receives FDA 510(k) Clearance for Ambulatory Infusion Pump

Fri, 10/24/2014 - 13:04
A Simple, Safe, and Reliable Ambulatory Infusion System NATICK, Mass., Oct. 24, 2014 -- (Healthcare Sales & Marketing Network) -- Zyno Medical, LLC today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) i...
Devices, FDA
Zyno Medical, Nimbus, ambulatory infusion system

QLT Appoints Dr. Geoffrey F. Cox as Interim Chief Executive Officer

Fri, 10/24/2014 - 13:00
Announces 2014 Annual General Meeting Date VANCOUVER, British Columbia, Oct. 24, 2014 -- (Healthcare Sales & Marketing Network) -- QLT Inc. (QLTI) (QLT.TO) ("QLT" or the "Company") today announced that current QLT Board member, Geoff...
Biopharmaceuticals, Ophthalmology, Personnel

The TransMedics(R) Organ Care System (OCS(TM)) Heart Technology Was Used to Perform The World's First Series of Adult Human Heart Transplants From Donors After Circulatory Death (DCD Donors) at St Vincent's Hospital in Sydney, Australia

Fri, 10/24/2014 - 12:53
ANDOVER, Mass. , Oct. 24, 2014 (Healthcare Sales & Marketing Network) -- TransMedics announces that its OCS ™ Heart technology was used to preserve and assess the world's first series of three successful adult heart transplant procedures from hearts donate...
Devices, Cardiology
TransMedics, Organ Care System, OCS Heart, transplantation

Aurora Spine Announces Expansion of U.S. Hospital Network Through Agreement With MedAssets

Thu, 10/23/2014 - 16:11
CARLSBAD, CALIFORNIA--(Healthcare Sales & Marketing Network) - Aurora Spine Corporation (TSX VENTURE:ASG) announced it has entered into a national contract with MedAssets. MedAssets is one of the nation's largest third-party providers of supply chain manag...
Devices, Orthopaedic, Neurosurgery, Distribution
Aurora Spine, MedAssets

AbVitro Inc. Appoints Jeffrey M. Ostrove, Ph.D. as Chief Executive Officer

Thu, 10/23/2014 - 16:08
BOSTON, Oct. 23, 2014 -- (Healthcare Sales & Marketing Network) -- AbVitro Inc., a therapeutic target discovery company, announced that Jeffrey M. Ostrove, Ph.D. has been appointed as chief executive officer and director of the Company. Dr. Ostrove brings...
Biopharmaceuticals, Personnel

Quartet Medicine Launches with $17 Million Series A Financing

Thu, 10/23/2014 - 15:51
Company to explore broad applications for modulators of tetrahydrobiopterin (BH4) synthesis in the treatment of chronic pain and inflammation CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Quartet Medicine, a biotechnology company focused on ...
Biopharmaceuticals, Venture Capital
Quartet Medicine, tetrahydrobiopterin

Raptor Pharmaceutical Announces Management Changes

Thu, 10/23/2014 - 15:48
NOVATO, Calif., Oct. 23, 2014 -- (Healthcare Sales & Marketing Network) -- Raptor Pharmaceutical Corp. (RPTP) today announced that it has strengthened its leadership team with the hiring of two new executives: David Happel, Chief Commercial Officer, who wi...
Biopharmaceuticals, Personnel
Raptor Pharmaceutical, nephropathic cystinosis

Gamma Medica Secures $11.5 Million in Growth Financing

Wed, 10/22/2014 - 15:47
Award-winning molecular breast imaging company plans global marketing and sales expansion SALEM, N.H.--(Healthcare Sales & Marketing Network)--Gamma Medica, a developer of advanced digital molecular imaging technologies, announced today a $6.5 million g...
Devices, Radiology, Oncology, Venture Capital
Gamma Medica, LumaGEM, Molecular Breast Imaging

Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors

Wed, 10/22/2014 - 15:44
MADISON, N.J., Oct. 22, 2014 -- (Healthcare Sales & Marketing Network) -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Jeffrey M. Leiden, M.D., Ph.D., to ...
Diagnostics, Personnel
Quest Diagnostics

aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research

Wed, 10/22/2014 - 15:41
Architect of Novel Translational Rare Disease Programs at NIH Adds Depth to Existing Team of Rare Disease Experts SAN DIEGO and HONG KONG, Oct. 22, 2014 -- (Healthcare Sales & Marketing Network) -- aTyr Pharma ("aTyr"), an innovative rare dis...
Biopharmaceuticals, Personnel
aTyr Pharma, Physiocrine

Atossa Genetics Receives CE Mark for the ForeCYTE Breast Aspirator Device

Wed, 10/22/2014 - 15:37
SEATTLE, WA--(Healthcare Sales & Marketing Network) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced it has received certification to Annex II of the European Medical Device Directive (MDD) from its European Notified Body, DQS Medizinprodukte GmbH, wh...
Devices, Diagnostics, Oncology, Regulatory
Atossa Genetics, ForeCYTE Breast Aspirator

Otonomy Appoints Anthony J. Yost Chief Commercial Officer

Tue, 10/21/2014 - 12:46
SAN DIEGO, Oct. 21, 2014 -- (Healthcare Sales & Marketing Network) -- Otonomy, Inc. (OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and m...
Biopharmaceuticals, Personnel
Otonomy Inc

Viamet Announces $60 Million Series D Financing

Tue, 10/21/2014 - 12:40
RESEARCH TRIANGLE PARK, N.C.--(Healthcare Sales & Marketing Network)--Viamet Pharmaceuticals Holdings, LLC (Viamet) today announced the closing of a $60 million Series D financing provided by Brandon Point Industries Limited (Brandon Point) working with Wo...
Biopharmaceuticals, Venture Capital
Viamet Pharmaceuticals

NeuroSigma Receives Notice of Allowance of U.S. Patent Application

Tue, 10/21/2014 - 12:35
Subcutaneous Trigeminal Nerve Stimulation (sTNS) for the Treatment of Neuropsychiatric Disorders LOS ANGELES, Oct. 21, 2014 -- (Healthcare Sales & Marketing Network) – NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused...
Devices, Neurology
NeuroSigma, Monarch eTNS system, trigeminal nerve stimulation

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong